$4.76
0.02[0.42%]
At close: Apr 16
$4.76
0[0.00%]
PreMarket: 4:00AM EDT
Medical Properties Trust
(NYSE:MPW)Medical Properties Trust Stock (NYSE:MPW), Analyst Ratings, Price Targets, Predictions
Medical Properties Trust Inc has a consensus price target of $9.23, established from looking at the 66 latest analyst ratings. The last 3 analyst ratings were released from Truist Securities, Exane BNP Paribas, and RBC Capital on April 8, 2024, March 1, 2024, and February 20, 2024. With an average price target of $5.17 between Truist Securities, Exane BNP Paribas, and RBC Capital, there's an implied 8.54% upside for Medical Properties Trust Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Exane BNP Paribas
RBC Capital
Deutsche Bank
Keybanc
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Medical Properties Trust
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/08/2024 | MPW | Buy Now | Medical Properties Trust | $4.76 | -5.46% | Truist Securities | Michael Lewis | $4 → $4.5 | Maintains | Hold | Get Alert |
| 03/01/2024 | MPW | Buy Now | Medical Properties Trust | $4.76 | 26.05% | Exane BNP Paribas | Nate Crossett | → $6 | Upgrade | Neutral → Outperform | Get Alert |
| 02/20/2024 | MPW | Buy Now | Medical Properties Trust | $4.76 | 5.04% | RBC Capital | Michael Carroll | $8 → $5 | Maintains | Outperform | Get Alert |
| 01/30/2024 | MPW | Buy Now | Medical Properties Trust | $4.76 | -57.98% | Deutsche Bank | Omotayo Okusanya | → $2 | Initiates | → Sell | Get Alert |
| 01/05/2024 | MPW | Buy Now | Medical Properties Trust | $4.76 | — | Keybanc | Austin Wurschmidt | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 01/03/2024 | MPW | Buy Now | Medical Properties Trust | $4.76 | 47.06% | Mizuho | Vikram Malhotra | $9 → $7 | Maintains | Neutral | Get Alert |
| 11/29/2023 | MPW | Buy Now | Medical Properties Trust | $4.76 | 5.04% | JP Morgan | Michael Lapides | $8 → $5 | Maintains | Underweight | Get Alert |
| 11/10/2023 | MPW | Buy Now | Medical Properties Trust | $4.76 | -5.46% | Stifel | Stephen Manaker | $12 → $4.5 | Downgrade | Buy → Hold | Get Alert |
| 10/17/2023 | MPW | Buy Now | Medical Properties Trust | $4.76 | -15.97% | Wells Fargo | Connor Siversky | $7 → $4 | Maintains | Underweight | Get Alert |
| 10/16/2023 | MPW | Buy Now | Medical Properties Trust | $4.76 | -15.97% | Wells Fargo | Connor Siversky | → $4 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 09/25/2023 | MPW | Buy Now | Medical Properties Trust | $4.76 | 110.08% | RBC Capital | Michael Carroll | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 08/31/2023 | MPW | Buy Now | Medical Properties Trust | $4.76 | 89.08% | Mizuho | Vikram Malhotra | $18 → $9 | Downgrade | Buy → Neutral | Get Alert |
| 08/22/2023 | MPW | Buy Now | Medical Properties Trust | $4.76 | 110.08% | Barclays | Steve Valiquette | $12 → $10 | Maintains | Overweight | Get Alert |
| 08/21/2023 | MPW | Buy Now | Medical Properties Trust | $4.76 | 47.06% | JP Morgan | Michael Lapides | $9 → $7 | Downgrade | Neutral → Underweight | Get Alert |
| 08/14/2023 | MPW | Buy Now | Medical Properties Trust | $4.76 | 110.08% | RBC Capital | Michael Carroll | $12 → $10 | Maintains | Outperform | Get Alert |
| 08/11/2023 | MPW | Buy Now | Medical Properties Trust | $4.76 | 68.07% | B of A Securities | Joshua Dennerlein | $9 → $8 | Downgrade | Neutral → Underperform | Get Alert |
| 08/11/2023 | MPW | Buy Now | Medical Properties Trust | $4.76 | — | Raymond James | Jonathan Hughes | — | Downgrade | Strong Buy → Underperform | Get Alert |
| 06/23/2023 | MPW | Buy Now | Medical Properties Trust | $4.76 | 110.08% | Truist Securities | Michael Lapides | $9 → $10 | Maintains | Hold | Get Alert |
| 04/20/2023 | MPW | Buy Now | Medical Properties Trust | $4.76 | 89.08% | Wells Fargo | Connor Siversky | → $9 | Initiates | → Equal-Weight | Get Alert |
FAQ
What is the target price for Medical Properties Trust (MPW)?
The latest price target for Medical Properties Trust (NYSE: MPW) was reported by Truist Securities on April 8, 2024. The analyst firm set a price target for $4.50 expecting MPW to fall to within 12 months (a possible -5.46% downside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Medical Properties Trust (MPW)?
The latest analyst rating for Medical Properties Trust (NYSE: MPW) was provided by Truist Securities, and Medical Properties Trust maintained their hold rating.
When was the last upgrade for Medical Properties Trust (MPW)?
The last upgrade for Medical Properties Trust Inc happened on March 1, 2024 when Exane BNP Paribas raised their price target to $6. Exane BNP Paribas previously had a neutral for Medical Properties Trust Inc.
When was the last downgrade for Medical Properties Trust (MPW)?
The last downgrade for Medical Properties Trust Inc happened on January 5, 2024 when Keybanc changed their price target from N/A to N/A for Medical Properties Trust Inc.
When is the next analyst rating going to be posted or updated for Medical Properties Trust (MPW)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medical Properties Trust, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medical Properties Trust was filed on April 8, 2024 so you should expect the next rating to be made available sometime around April 8, 2025.
Is the Analyst Rating Medical Properties Trust (MPW) correct?
While ratings are subjective and will change, the latest Medical Properties Trust (MPW) rating was a maintained with a price target of $4.00 to $4.50. The current price Medical Properties Trust (MPW) is trading at is $4.76, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.